Observational Study in Japanese Patients With Peripheral T-Cell Lymphoma Who Received Second-Line Therapy
Sponsor: Bristol-Myers Squibb
This observational or N/A phase trial investigates Peripheral T-cell Lymphoma and is currently completed. Bristol-Myers Squibb leads this study, which shows 5 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Jul 2025 — Present [monthly]
Completed
Status: Recruiting → Completed
-
Nov 2024 — Jul 2025 [monthly]
Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Recruiting
First recorded
Apr 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
For direct contact, visit the study record on ClinicalTrials.gov .